Navigation Links
Shire's INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
Date:5/18/2009

San Francisco, CA May 18, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the ADHD Rating Scale-IV (ADHD-RS-IV), a scale frequently used in ADHD clinical trials. In results from this study presented today, INTUNIV also demonstrated sy
'/>"/>

Contact: Debra Gemme
debra.gemme@porternovelli.com
212-601-8342
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
2. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
3. New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
4. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
5. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
6. Cipher receives tentative FDA approval for extended-release tramadol capsules
7. Bioniche Warrants Expiration Date to be Extended
8. Teaching Hospitals Post-Op Gains Not Extended to Blacks
9. Stroke therapy window might be extended past nine hours for some
10. Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio
11. Get Screened Video Contest Deadline Extended to Jan. 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Barbara Williamson shares her life story ... "An Extraordinary Life: Love, Sex and Commitment" . As ... of the highly successful and controversial Sandstone Retreat in ... the couple started what became known as the hub ... Retreat was outrageously popular, with a membership reaching 500 ...
(Date:9/30/2014)... September 30, 2014 Computer Resources ... solutions firm based in New York City, has ... Manage360° solution to transform, manage, and support the ... who is a leading provider of innovative services ... self sufficient. The contract will cover the ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release ... Complex Social Age by Frank Guglielmo and ... the authors apply their leadership coaching experience to introduce Social ... actions, and behaviors that leaders must adopt in order to ... to read a review of The Social Leader in Dialogue ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 RBS Reputation Management ... service named ‘Remove Your Name’. , The service name ... reason behind giving the service this odd name, a management ... nothing odd in this name. We have named the service ... as organizations to get rid of all those posts which ...
(Date:9/30/2014)... 30, 2014 A trailblazer at heart, Dr. ... out upcoming medical breakthroughs in spine repairs. His newest ... in his patients in which he has implanted the ... components are state-of-the art and mimic normal human disc motion. ... also been proven to be an exceptional replacement device for ...
Breaking Medicine News(10 mins):Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:RBS Reputation Management Announces A New Service ‘Remove Your Name’ 2
... FL, June 30, 2010 The Florida Biomedical Research ... to three scientists from the Florida campus of The ... to Glenn Micalizio, an associate professor in the Scripps ... five years; Thomas Bannister, assistant professor of medicinal chemistry ...
... Scientists at the Stanford University School of Medicine ... finding is significant because the existence of such a ... source of debate. It may also explain why current ... human patients. "These cells lack the traditional ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, June ... daughter avoid dementia much later on in life, a new study ... to play. Canadian researchers believe they,ve found a link between ... senior years. The study doesn,t definitively prove that exercise lowers ...
... People who care about improving the environment in life may ... Europe have developed two new and unusual methods of body ... compost method that turns bodies into soil that could ... the topic of an article in the current issue of ...
... Glinert and Jon Schommer, the associate head of the ... University of Minnesota, have examined the corporate websites dedicated ... startling lack of consistency in an industry where advertising ... (FDA). "Communicating via a website is common ...
... ... ... -- Practical solutions and protocols will once again be exchanged at Cambridge Healthtech ... Boston. The four meetings comprising the event (Optimizing Cell Culture Technology, Affinity ...
Cached Medicine News:Health News:Scripps Research scientists share $2 million in Florida state research grants 2Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Exercise May Guard Girls Against Dementia in Senior Years 2Health News:Linguistics professor examines manufacturers' prescription drug websites 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 3
(Date:9/29/2014)... CAMBRIDGE, Mass. , Sept. 29, ... Group, Inc. (KEW), a privately held oncology services ... companies to make KEW,s state-of-the-art diagnostic services available ... KEW is a privately held oncology services company ... empowering all oncologists to access and apply genomic ...
(Date:9/29/2014)... Novogen Ltd. (ASX: NRT, NASDAQ: NVGN ) CEO ... with ABC TV that was broadcast on Saturday September 27th ... following day on Weekend Breakfast. The interview concerned the Company,s ... in Australia for the treatment of ... The interview provides certain new information and is being announced ...
(Date:9/29/2014)... , Sept. 29, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today the closing ... offering.  As previously disclosed, Lpath sold 3,605,042 registered ... 3,605,042 unregistered shares of common stock in a ... $3.475 per share-and-warrant-share combination.  The warrants have an ...
Breaking Medicine Technology:Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 2Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 4ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 2ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 3Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering 3
... PARK, Fla., Feb. 27, 2012 WHAT: Gearing up for its 2012 ... Fla., Transitions Optical, in conjunction with the Coconut Grove Chamber ... national travel expert Marybeth Bond, has listed the "Top 25 ... and is asking travel enthusiasts – tourists and Miami locals ...
... Calif., Feb. 27, 2012 Masimo (NASDAQ: MASI ) ... 24th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in ... Pacific Time.  A live audiocast of the presentation will be available ... the audiocast will be available following the live presentation. ...
Cached Medicine Technology:Transitions Optical Kicks-Off 2012 Multi-City "Sightseeing City Tour" with Voting Contest for "Top 10 Sights to See" in Miami 2Masimo to Present at 24th Annual ROTH Conference 2Masimo to Present at 24th Annual ROTH Conference 3
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
... voltage power supply, the 105 is very simple ... switch control the output, which is variable in ... two-position switch toggles the bright LED display from ... is equipped with an over current detector for ...
... supply is capable of producing up to 250 ... operates in constant voltage or constant current with ... over from one mode of operation to the ... A dual function, auto ranging 24-hour up/down ...
... is designed for horizontal and vertical gel ... be accomplished. In this power supply model, ... current or constant voltage. Four sets of ... connected simultaneously. This power supply's light, compact ...
Medicine Products: